This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About CRESEMBA®About CRESEMBA®Meet CRESEMBA®CRESEMBA® in the ICUCRESEMBA® in ActionEfficacy EfficacyInvasive AspergillosisEfficacyGuidelines MucormycosisEfficacyGuidelinesSafetySafetyTolerabilityInvasive AspergillosisMucormycosis Safety ProfileSafety ProfileDosingDosingSimple DosingLinear PKs, Low Variability and TDMPractical ConsiderationsReal-world DataReal-world DataReal-world EffectivenessReal-world SafetyResourcesResourcesSummary of Prescribing InformationEventsMaterialsVideos

An alternative antifungal option for the ICU: Meet CRESEMBA®

Almost half of all cases of invasive aspergillosis and a high proportion of mucormycosis cases are diagnosed or treated in the ICU1,2

  

Whilst diagnostics and treatment have progressed, invasive fungal infections continue to pose a serious threat and are associated with extremely high mortality.3–6

Invasive aspergillosis and mucormycosis typically affect individuals who are immunocompromised and/or have established risk factors,2,7–10 but cases are also being reported in critically ill patients admitted to the ICU.7,8,10 Establishing a diagnosis in this setting can be challenging as the classic diagnostic definitions (EORTC/MSGERC) for invasive fungal disease were created primarily for patients with cancer and stem cell or solid organ transplant,7,11 and the ICU patient population may present with different features.11–13

Badge Underlying conditions in ICU patients with invasive aspergillosis (n=297)7 Kicker

Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Button Loading

Adapted from reference 7.


An emerging association between COVID-19 and pulmonary aspergillosis/mucormycosis14–18

The global pandemic has shown that invasive mould infections such as aspergillosis and mucormycosis can represent an additional threat to COVID-19 patients who are admitted to the ICU or develop ARDS:14–18 cases of COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM) are increasingly being reported.19 Clinical and radiological signs of CAPA and CAM can overlap – and there have been reports of simultaneous mixed superinfection.18–20

Badge Critically ill patients can develop invasive aspergillosis in the ICUaAdapted from references 12, 21-26.

a. Cases of invasive aspergillosis (mainly pulmonary) reported among ICU patients in different prospective and retrospective studies.

Button Loading

Adapted from references 12, 21-26.

How can CRESEMBA® help your patients?

In the complicated clinical scenario ICU patients often find themselves in, think CRESEMBA®:

  • Improved safety and tolerability vs voriconazole27
  • A linear PK profile with low inter- and intra-patient variability, unlike other azoles3,28–30
  • Fewer drug–drug interactions vs other azoles3,28
  • No dose adjustment required in patients with renal impairment, including those with ESRD28
  • Simple and reliable dosing28

CRESEMBA® can offer the flexibility you need, so that you can focus on your patient’s underlying condition.3,4,27,28

  

ARDS, acute respiratory distress syndrome; BMT, bone marrow transplant; CAM, COVID-19-associated mucormycosis; CAPA, COVID-19-associated pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; EORTC/MSGERC, European Organization for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; ICU, intensive care unit; PK, pharmacokinetic.

Prescribing Information:
CRESEMBA
® (isavuconazole)

References:

Bassetti M et al. IDCases 2018;7–9.Bassetti M and Bouza E. J Antimicrob Chemother 2017;72(Suppl 1):i39–i47.Natesan SK and Chandrasekar PH. Infect Drug Resist 2016;9:291–300.Perfect JR. Nat Rev Drug Discov 2017;16(9):603–616.Binder U and Lass-Florl C. Mediterr J Hematol Infect Dis 2011;3(1):e20110016.Low CY and Rotstein C. F1000 Med Rep 2011;3:14.Taccone FS, et al. Crit Care 2015;19:7.ECDC. Influenza-associated invasive pulmonary aspergillosis, Europe. 2018. Available at: https://www.ecdc.europa.eu/sites/portal/files/documents/aspergillus-and-influenza-rapid-risk-assessment-november-2018.pdf. Accessed May 2022.Baddley JW. Med Mycol 2011;49(Suppl 1):S7–S12.Bassetti M et al. Infect Dis Ther 2018;7(1):17–27.Bassetti M et al. Clin Infect Dis 2021;72(Suppl 2):S121–S127.Delsuc C et al. Crit Care 2015;19:421. De Pauw B et al. Clin Infect Dis 2008;46(12):1813–1821.Arastehfar A et al. J Fungi (Basel) 2020;6(2):91.Alanio A et al. Lancet Respir Med 2020;8(6):e48–e49.Rutsaert L et al. Ann Intensive Care 2020;10(1):71.Song G et al. Mycopathologia 2020;185(4):599–606.Hoenigl M et al. SSRN. 2021. [Epub ahead of print]. Available at: https://ssrn.com/abstract=3844587 or http://dx.doi.org/10.2139/ssrn.3844587. Accessed May 2022Benhadid-Brahmi Y, et al. JMM 2022;32(1):101231.Garg D, et al. Mycopathologia 2021;186:289–298.Schauwvlieghe AFAD, et al. Lancet Respir Med 2018;6(10):782–792.Wauters J et al. Intensive Care Med 2012;38(11):1761–1768.Gustot T et al. J Hepatol 2014;60(2):267–274.Verweij PE et al. Intensive Care Med 2021;47(8):819–834.Contou D et al. Ann Intensive Care 2016;6(1):52.Levesque E et al. Ann Intensive Care 2019;9(1):31.Maertens JA et al. Lancet 2016;387(10020):760–769.Adapted from Local Product Document of CRESEMBA® (Isavuconazole) version LPDCRE052021.Kaindl T et al. J Antimicrob Chemother 2018:74(3):761–767.Schmitt-Hoffmann A et al. Antimicrob Agents Chemother 2006;50(1):279–285.

PP-CRB-IND-0472 July 2022

About CRESEMBA® In a complicated environment, why not consider an effective antifungal that you can rely on? Find Out More  In a complicated environment, why not consider an effective antifungal that you can rely on? Find Out More  Are underlying conditions impacted by using CRESEMBA®? View Safety Profile How does the efficacy of CRESEMBA® translate into real-world safety? Learn More


How does the efficacy of CRESEMBA® translate into real-world safety? Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-CRB-IND-0472

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​